drugset / Trial / NCT01802996

Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

NCT01802996

Phase 4 Unknown 2040 enrolled Cttq
RandomizedParallel-groupOpen-labelPrevention

Summary

This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.

Timeline

Start
2013-03
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Isoglycyrrhizinate Unknown 200 mg Intravenous